ABSTRACT
INTRODUCTION Clinical use of peptide and protein-based drugs is currently increasing in ophthalmology. This is due to the launching of the monoclonal antibodies for the treatment of age-related macular degeneration. These drugs have superior clinical efficacy to the prior available therapies, with improved outcomes in the treatment of age-related macular degeneration (1). Antibodies directed against vascular endothelial growth factor (VEGF) alleviate problems associated with neovascularization of the posterior segment of the eye. These antibodies are injected directly into the vitreous humor of the patients. Because of the invasive nature of this mode of drug delivery, improved methods of ocular protein and peptide delivery are being investigated.
